Abstract
ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor‐2 (KDR) tyrosine kinase, with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. ZD6474 has been shown to inhibit angiogenesis and tumor growth in a range of tumor models. Gefitinib (“Iressa”) is an selective EGFR tyrosine kinase inhibitor (TKI) that blocks signal transduction pathways. We examined the antitumor activity of ZD6474 in the gefitinib‐sensitive lung adenocarcinoma cell line, PC‐9, and a gefitinib‐resistant variant (PC‐9/ZD). PC‐9/ZD cells showed cross‐resistance to ZD6474 in an in vitro dye formation assay. In addition, ZD6474 showed dose‐dependent inhibition of EGFR phosphorylation in PC‐9 cells, but inhibition was only partial in PC‐9/ZD cells. ZD6474‐mediated inhibition of tyrosine residue phosphorylation (Tyr992 and Tyr1045) on EGFR was greater in PC‐9 cells than in PC‐9/ZD cells. These findings suggest that the inhibition of EGFR phosphorylation by ZD6474 can contribute a significant, direct growth‐inhibitory effect in tumor cell lines dependent on EGFR signaling for growth and/or survival. The effect of ZD6474 (12.5–50 mg/kg/day p.o. for 21 days) on the growth of PC‐9 and PC‐9/ZD tumor xenografts in athymic mice was also investigated. The greatest effect was seen in gefitinib‐sensitive PC‐9 tumors, where ZD6474 treatment (>12.5 mg/kg/day) resulted in tumor regression. Dose‐dependent growth inhibition, but not tumor regression, was seen in ZD6474‐treated PC‐9/ZD tumors. These studies demonstrate that the additional EGFR TKI activity may contribute significantly to the anti‐tumor efficacy of ZD6474, in particular in those tumors that are dependent on continued EGFR‐signaling for proliferation or survival. In addition, these results provide a preclinical rationale for further investigation of ZD6474 as a potential treatment option for both EGFR‐TKI‐sensitive and EGFR‐TKI‐resistant tumors.
AAbbreviations:
- VEGF
vascular endothelial growth factor
- EGFR
epidermal growth factor receptor
- TKI
tyrosine kinase inhibitor
- NSCLC
non‐small cell lung cancer
- MTT
3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide
References
- 1. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor ty‐rosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546–56. [PubMed] [Google Scholar]
- 2. Ciardiello F, Bianco R, Caputo R, Damiano V, Troiani T, Melisi D, de Vita F, de Placido S, Bianco AR, Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784–93. [DOI] [PubMed] [Google Scholar]
- 3. Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22: abstr 778. [Google Scholar]
- 4. 1 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Am Soc Clin Oncol 2002; 22: abstr 325. [Google Scholar]
- 5. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, de Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD‐1839 (Iressa), an epidermal growth factor receptor‐selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053–63. [PubMed] [Google Scholar]
- 6. 1 The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2‐driven signaling and suppresses the growth of HER2‐overexpressing tumor cells. Cancer Res 2001; 61: 7184–8. [PubMed] [Google Scholar]
- 7. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CFT‐11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004; 108: 464–72. [DOI] [PubMed] [Google Scholar]
- 8. Koizumi F, Taguchi F, Shimoyama T, Saijo N, Nishio K. Mechanism of resistance to epidermal growth factor receptor inhibitor ZD1839: a role for inhibiting phosphorylation of EGFR at Tyrl068. Am Assoc Cancer Res 2003: abstr 1001. [Google Scholar]
- 9. Kawamura‐Akiyama Y, Kusaba H, Kanzawa F, Tamura T, Saijo N, Nishio K, Arioka H, Ishida T, Fukumoto H, Kurokawa H, Sata M, Ohata M, Morikage T, Ohmori T, Fujiwara Y, Takeda Y. Non‐cross resistance of ZD0473 in acquired cisplatin‐resistant lung cancer cell lines. Lung Cancer 2002; 38: 43–50. [DOI] [PubMed] [Google Scholar]
- 10. Nishio K, Arioka H, Ishida T, Fukumoto H, Kurokawa H, Sata M, Ohata M, Saijo N, Morikage T, Ohmori T, Fujiwara Y, Takeda Y. Enhanced interaction between tubulin and microtubule‐associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer 1995; 63: 688–93. [DOI] [PubMed] [Google Scholar]
- 11. Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K. Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo . Int J Cancer 2002; 98: 310–5. [DOI] [PubMed] [Google Scholar]
- 12. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non‐small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal‐regulated kinase 1/2 and EGF receptor/ Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465–72. [PubMed] [Google Scholar]
- 13. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–55. [PubMed] [Google Scholar]
- 14. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883–93. [DOI] [PubMed] [Google Scholar]
- 15. Holbrook MR, O'Donnell JB Jr, Slakey LL, Gross DJ, Bishayee A, Beguinot L, Bishayee S. Epidermal growth factor receptor internalization rate is regulated by negative charges near the SH2 binding site Tyr992. Biochemistry 1999; 38: 9348–56. [DOI] [PubMed] [Google Scholar]
- 16. Bishayee A, Beguinot L, Bishayee S. Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c‐terminal tail. Mol Biol Cell 1999; 10: 525–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Nogami M, Yamazaki M, Watanabe H, Okabayashi Y, Kido Y, Kasuga M, Sasaki T, Maehama T, Kanaho Y, Holbrook MR, O'Donnell JB Jr, Slakey LL, Gross DJ, Bishayee A, Beguinot L, Bishayee S. Requirement of auto‐phosphorylated tyrosine 992 of EGF receptor and its docking protein phospholipase C gamma 1 for membrane ruffle formation. FEBS Lett 2003; 536: 71–6. [DOI] [PubMed] [Google Scholar]
- 18. Ravid T, Sweeney C, Gee P, Carraway KL 3rd, Goldkorn T. Epidermal growth factor receptor activation under oxidative stress fails to promote c‐Cbl mediated down‐regulation. J Biol Chem 2002; 277: 31214–9. [DOI] [PubMed] [Google Scholar]